Palmer T, et al. - In this study involving 138,692 women, researchers quantified the impact of immunization with bivalent human papillomavirus (HPV) vaccine at age 12-13 years on the cervical disease at 20 years of age. According to findings, routine vaccination of girls (aged 12-13) with the bivalent HPV vaccine has led to a dramatic reduction in pre-invasive cervical disease in Scotland. In unvaccinated women, they observed evidence of clinically relevant herd protection. These data are consistent with the decreased prevalence of high-risk HPV in this region. Overall, the bivalent vaccine was highly effective, and the incidence of cervical cancer was greatly reduced. These results may have implications for cervical cancer prevention programs worldwide.